The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic effects of 2B8T2M, a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody in combination with expanded natural killer cells against rituximab sensitive and resistant Burkitt lymphoma (BL).
 
Yaya Chu
No Relationships to Disclose
 
Nang Kham Su
No Relationships to Disclose
 
Sarah Alter
No Relationships to Disclose
 
Emily Jeng
Employment - Altor BioScience
 
Peter R. Rhode
Employment - Altor BioScience
 
Matthew John Barth
No Relationships to Disclose
 
Dean Anthony Lee
Employment - Cyto-Sen Therapeutics
Consulting or Advisory Role - Courier Therapeutics; Intellia Therapeutics
Speakers' Bureau - Miltenyi Biotec
Other Relationship - Cyto-Sen Therapeutics
 
Hing C. Wong
Employment - Altor BioScience
 
Mitchell S. Cairo
No Relationships to Disclose